Lantern Pharma Launches AI-Powered ZetaOmics Platform to Advance Precision Oncology

Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company headquartered in Dallas, Texas, has announced the launch of ZetaOmics, the computational biology module of its multi-agentic AI co-scientist platform withZeta.ai. The new module introduces an autonomous “Computational Biologist” agent designed to perform end-to-end bioinformatics and multi-omic analysis across cancer types. Initially available through an early-access program for select academic, industry and company collaborators, the platform is designed to automate complex research workflows while embedding domain-specific intelligence intended to improve analytical rigor and reproducibility.

According to the company, ZetaOmics combines 14 specialized tools that can autonomously design, execute and validate biological analyses, detect potential flaws in experimental design and generate publication-quality results with a complete audit trail. This capability is expected to significantly reduce the time and effort required for bioinformatics analysis, allowing researchers to focus on interpreting results and advancing cancer therapies. Lantern said the platform expands withZeta.ai’s commercial opportunity beyond rare cancers by targeting academic medical centers, biotechnology and pharmaceutical companies, cancer centers and contract research organizations through subscription-based offerings and strategic collaborations.

The launch of ZetaOmics represents a key milestone for Lantern Pharma as it transitions from a clinical-stage company to a provider of AI tools for the broader biomedical community. WithZeta.ai, Lantern’s multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the Company. This move could have significant implications for the Texas biotech ecosystem, positioning the state as a hub for AI-driven drug discovery and precision medicine.

Lantern Pharma’s clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary. The company operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.

The announcement is particularly important for researchers and pharmaceutical companies seeking to accelerate oncology research. By automating bioinformatics workflows and ensuring reproducibility, ZetaOmics could help reduce the high failure rates in drug development and bring new therapies to patients faster. For the Texas economy, the expansion of Lantern Pharma’s AI platform reinforces the state’s growing leadership in biotechnology and artificial intelligence. For more information, visit https://ibn.fm/9sIIl.